Article FDA Thank You The next chapter in the ctDNA story: Still promising, not ready for prime time
Agency IQ
JULY 21, 2023
As for the second challenge, potential confounders present at the time of treatment initiation can be controlled for using randomization, but it may be more difficult for sponsors to detect and adjust for factors that arise after the investigational product’s administration (e.g.,
40 
Let's personalize your content